Conference item
A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 168.9KB, Terms of use)
-
- Publisher copy:
- 10.1093/ecco-jcc/jjx180.486
Authors
- Publisher:
- Oxford University Press
- Host title:
- Journal of Crohn's and Colitis
- Journal:
- Journal of Crohn's and Colitis More from this journal
- Volume:
- 12
- Issue:
- supplement_1
- Pages:
- S285–S286
- Publication date:
- 2018-01-16
- Acceptance date:
- 2018-01-16
- DOI:
- EISSN:
-
1876-4479
- ISSN:
-
1873-9946
- Pubs id:
-
pubs:844217
- UUID:
-
uuid:389cc7fa-f070-411b-ac12-938f49894513
- Local pid:
-
pubs:844217
- Source identifiers:
-
844217
- Deposit date:
-
2018-09-23
Terms of use
- Copyright holder:
- European Crohn’s and Colitis Organisation (ECCO)
- Copyright date:
- 2018
- Notes:
- © 2018 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. This is the author accepted manuscript following peer review version of the article. The final version is available online from Oxford University Press at: 10.1093/ecco-jcc/jjx180.486
If you are the owner of this record, you can report an update to it here: Report update to this record